| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026075123 |
| P356 | DOI | 10.2165/11587420-000000000-00000 |
| P698 | PubMed publication ID | 21182341 |
| P50 | author | Mark A Boyd | Q61799658 |
| P2093 | author name string | Andrew M Hill | |
| P2860 | cites work | Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial | Q73368842 |
| Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation | Q74752896 | ||
| Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial | Q77975748 | ||
| Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails | Q79497488 | ||
| Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 | Q79776867 | ||
| Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients | Q80112851 | ||
| New HIV drug classes on the horizon | Q80213979 | ||
| Improved survival in HIV-infected persons: consequences and perspectives | Q80563694 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes | Q24627714 | ||
| Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection | Q24672964 | ||
| Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America | Q28183380 | ||
| Raltegravir with optimized background therapy for resistant HIV-1 infection | Q28288290 | ||
| In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors | Q28373044 | ||
| Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study | Q28474221 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r | Q31051809 | ||
| Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Q31108441 | ||
| The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study | Q32054802 | ||
| Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro | Q32066787 | ||
| Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial | Q33587553 | ||
| HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort | Q33905127 | ||
| Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study | Q33934887 | ||
| Management of protease inhibitor-associated diarrhea | Q33943243 | ||
| The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy | Q33959260 | ||
| Decline in the AIDS and death rates in the EuroSIDA study: an observational study | Q33967061 | ||
| Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy | Q34003391 | ||
| Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity | Q34023081 | ||
| Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy | Q34155932 | ||
| The survival benefits of AIDS treatment in the United States | Q34533291 | ||
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection | Q34597895 | ||
| Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial | Q34647153 | ||
| Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens | Q34647483 | ||
| Adherence to HAART among patients with HIV: breakthroughs and barriers | Q34664263 | ||
| Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
| Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature | Q35057790 | ||
| Antiretrovirals, part 1: overview, history, and focus on protease inhibitors | Q35763212 | ||
| Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. | Q35768557 | ||
| The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? | Q35827071 | ||
| The entry of entry inhibitors: a fusion of science and medicine | Q35976966 | ||
| Cardiovascular risk and body-fat abnormalities in HIV-infected adults | Q36000980 | ||
| Protease-inhibitor boosting in the treatment-experienced patient. | Q36034394 | ||
| Drug interactions in the management of HIV infection | Q36066083 | ||
| Enfuvirtide: a review of its use in the management of HIV infection | Q36133801 | ||
| The management of HIV-1 protease inhibitor pharmacokinetic interactions | Q36154861 | ||
| The long-term consequences of antiretroviral therapy: a review | Q36596576 | ||
| An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults | Q36629125 | ||
| Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 | ||
| Class-sparing regimens for initial treatment of HIV-1 infection | Q37454026 | ||
| Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis | Q37531320 | ||
| Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials | Q38318950 | ||
| Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group | Q38476642 | ||
| Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). | Q39526764 | ||
| Virologic efficacy of boosted double versus boosted single protease inhibitor therapy | Q39640281 | ||
| Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n | Q39653073 | ||
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management | Q40396257 | ||
| TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates | Q40417023 | ||
| The AIDS epidemic--considerations for the 21st century | Q40795784 | ||
| Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults | Q43473501 | ||
| A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors | Q43613003 | ||
| Prevalence and predictive value of intermittent viremia with combination hiv therapy | Q43670221 | ||
| Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir | Q43671930 | ||
| Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens | Q43706922 | ||
| Drug resistance in patients experiencing early virological failure under a triple combination including indinavir | Q43730540 | ||
| Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia | Q43864142 | ||
| Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients | Q43917579 | ||
| Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen | Q44002783 | ||
| Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz | Q44238575 | ||
| Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia | Q44457921 | ||
| Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population | Q44510170 | ||
| Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures | Q44561806 | ||
| Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial | Q44579283 | ||
| Combination antiretroviral therapy and the risk of myocardial infarction | Q44662157 | ||
| Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine | Q44710862 | ||
| Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors | Q44811837 | ||
| The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team | Q44993614 | ||
| Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study | Q45013148 | ||
| Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen | Q45055063 | ||
| Update of the drug resistance mutations in HIV-1: Fall 2005. | Q45224966 | ||
| Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen | Q45272010 | ||
| Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus | Q45722048 | ||
| Immunopathogenesis of human immunodeficiency virus. | Q45754450 | ||
| Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients | Q46146170 | ||
| Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice | Q46375563 | ||
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
| Clinical and immunogenetic correlates of abacavir hypersensitivity | Q46500012 | ||
| A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. | Q46746589 | ||
| Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals | Q46803644 | ||
| Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 | ||
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910874 | ||
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910877 | ||
| Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. | Q53015851 | ||
| Twenty years of therapy for HIV-1 infection. | Q53382316 | ||
| Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). | Q53680395 | ||
| A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. | Q53977749 | ||
| Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. | Q53989578 | ||
| A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. | Q54044694 | ||
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes | Q56533400 | ||
| British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 | Q57180178 | ||
| Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study | Q57180242 | ||
| HIV Drug Resistance | Q59448085 | ||
| Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy | Q61790677 | ||
| P921 | main subject | HIV/AIDS | Q12199 |
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 17-34 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. | |
| P478 | volume | 28 Suppl 1 |
| Q39335635 | Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection |
| Q41665020 | Efficacy of raltegravir, etravirine and darunavir/ritonavir for treatment-experienced HIV patients from a non-urban clinic population in the United States |
| Q50145794 | HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge |
| Q37466832 | The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis |
Search more.